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The present study was designed to formulate colon release tablets of 
fluticasone by employing cross linked chitosan (CH) and carboxymethyl guar 
gum (CMG) interpolymer complexes (IPC). Matrix tablets were prepared by 
wet granulation method using IPC as binder and coating agent. The IPC were 
characterized by Fourier transform infrared spectroscopy (FTIR). The 
uncoated and coated tablets were tested for their suitability as colon specific 
drug delivery system by in vitro dissolution studies. The coated tablets were 
evaluated for their pharmacodynamic performance after oral administration 
to TNBS induced ulcerative colitic rats. FTIR studies demonstrated that the 
IPC was formed through an electrostatic interaction between –COO− groups 
of CMG and –NH3+ groups of CH. Tablets formulated with 50:50 CH:CMG 
as binder and coated with the respective ratio of IPC was capable of 
protecting the drug release in stomach and small intestine and delivering the 
drug in the colon. Histopathology of the rat colon after oral administration of 
these IPC film coated tablets revealed significantly greater (p<0.05) reduction 
in TNBS-induced ulcerative colitis The study confirmed that selective 
delivery of fluticasone to the colon can be achieved using cross-linked CH 
and CMG polysaccharides. 
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Inflammatory bowel disease (IBD) refers to two 
related but different diseases: ulcerative colitis (UC) 
and Crohn's disease (CD). These diseases cause 
chronic inflammation of the intestinal tract. IBD is a 
lifelong disease with periods of active disease 
alternating with periods of disease control 
(remission). It is widely estimated that between 1 and 
1.4 million people in the United States have IBD. 
Currently no curative therapeutic agent is available 
and treatment of IBD relies heavily on non-steroidal 
anti-inflammatory drug, glucocorticoids and immuno- 
 
modulators. The primary objective of anti-IBD 
therapy is to reduce the inflammation of colon. This 
requires frequent administration of anti-inflammatory 
drugs at high doses, which may lead to gastric 
ulceration, bleeding and other gastric complications 
[1]. Corticosteroids are the most effective agents in 
the treatment of acute UC because of their broad and 
nonspecific anti-inflammatory effects, including 
lymphocyte toxicity, inhibition of cytokines, and 
reduction of arachidonic acid metabolites [2].  
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Fluticasone is a fluorinated steroid which is both 
poorly absorbed and susceptible to high first pass 
metabolism. This compound has been primarily 
developed for topical use in asthma but its 
pharmacokinetic profile is very promising for 
inflammatory bowel disease [3].  
Delivery of the drugs to the colon via the oral route is 
valuable in treating diseases related to colon (Crohn’s 
disease, ulcerative colitis, irritable bowel disease, 
carcinomas and infections) whereby high local 
concentration of drugs can be achieved at the site of 
inflammation. Colon targeting can be achieved by 
pH-dependent systems or pH independent systems. 
Drug release in pH dependent systems is easily 
influenced by nature of diet. Further, physiologically, 
a highly alkaline pH of 7.4 of the small intestine often 
contributes to premature drug release and failure of 
the pH-dependent release systems before reaching the 
colon [4]. The pH-independent release systems suffer 
from the drawback of incomplete drug release and 
have to be combined with other polymers that are 
either soluble at colonic pH or are capable of being 
degraded by colonic bacteria [5]. 
Many researchers have reported the use of natural or 
modified polysaccharides for sustained or colon 
delivery of drugs. However, when employed in their 
putative form, these polysaccharides are required to 
be used in large quantities [6] for achieving colon 
drug delivery. This is probably due to high solubility 
of non-cross linked molecules in the acidic pH. 
Therefore, the recent emphasis is on the use of 
biodegradable polymer combinations that are cross 
linked with each other or with ions in order to render 
them insoluble in acidic pH. Chitosan-chondroitin 
sulphate interpolymer complexed film coated tablets 
have been reported for colon targeting [7]. Similarly, 
carboxymethyl tamarind kernel powder and chitosan 
interpolymer complexed film coated tablets have been 
reported for colon specific delivery of budesonide [8]. 
Chitosan (CH) carries a net positive charge due to –
NH3+ groups and can be easily cross-linked with other 
anions, oppositely charged drugs and polymers [9]. 
CH is easily degraded by lysozyme, by non specific 
cellulases and enzymes secreted by intestinal bacteria 
[10]. Guar gum has also been examined for use in 
colonic drug delivery [11]. However, natural gums 
being hydrophilic swell in the presence of dissolution 
media. Thus, there is a possibility of the entrapped 
drug leaking out prior to arrival of the dosage form at 
the site of absorption. Thus, there is a need to reduce 
the enormous swelling of the gums by cross linking. 
Carboxymethyl guar gum (CMG), a derivative of 
guar gum has been investigated for colon drug 
delivery. CMG microbeads were prepared by 
dropping a solution of CMG in a solution of divalent 
and trivalent metal ions. The Ba2+ cross-linked 
products were able to protect the drug under gastric 
pH conditions while Ca2+ ions cross-linked products 
were found to release the encapsulated drug when 
exposed to pH 7.4 i.e. intestinal pH [12]. 
In the light of the above, it was proposed to formulate 
tablets of fluticasone by using CH-CMG IPC as 
binder and coating them with aqueous mixtures 
containing respective ratios of CH-CMG IPC. The 
characterization of the IPC films was done by FTIR 
and water uptake studies. The effect of varying the 
composition of CH:CMG in the coating solution on 
the in vitro release of fluticasone from tablets was 
investigated. Further, the coated fluticasone tablets 
were evaluated for their pharmacodynamic 
performance after oral administration to TNBS 
induced colitic rats. 
 
Materials and methods 
Fluticasone propionate was gift sample from Cipla 
pharmaceuticals ltd. Mumbai (India). Guar gum was 
purchased from S.D fine chemicals, Mumbai (India). 
Chitosan (CH) was purchased from Indian sea foods, 
Cochin, India. Chitosanase was purchased from 
Sigma Aldrich, USA. Methanol used in analysis was 
of HPLC grade. All other chemicals used were of AR 
grade. 
 
Procedure for carboxymethylation of guar gum 
and characterization by FTIR  
Carboxymethylation was carried out using the method 
described by Ragheb et al., 1994 [13]. 100g of guar 
gum was added in a mixture of 630 ml of ethanol and 
554 ml of toluene. To this 44.8% w/v NaOH was 
added gradually and mixed thoroughly. This mixture 
was kept at room temperature for 30 min. 
Monochloro-acetic acid (120g) was gradually added 
with agitation to this mixture and kept overnight. The 
excess alkali was neutralized with glacial acetic acid 
using phenolphthalein indicator. The product was 
filtered, washed with ethanol and dried. The degree of 
substitution of CMG was determined by titrimetric 
method [14].  




Preparation of CH-CMG interpolymer complexed 
films  
CH (300 mg) was dissolved in 15 ml solution of 3%, 
v/v acetic acid. To this mixture 8 ml of 5 M-
ammonium acetate was added. CMG (300 mg) was 
separately dissolved in 7ml distilled water and slowly 
added with stirring to CH solution. This mixture was 
poured in petri plates and dried at 50 °C for 48 h. 
Films with a total polymer content of 2.5% w/v 
containing 60:40, 50:50 or 40:60 ratio of CH:CMG 
were prepared using this method. The dried films 
were stored in a desiccator until use.  
 
Characterization of IPC films  
FTIR studies  
CH, CMG and IPC films formed by drying 
admixtures containing different ratios of CH:CMG 
were subjected to FTIR analysis (Perkin Elmer RXI, 
USA). The fresh films were sequentially exposed to 
pH 1.2 buffer IP [15] for 2h and pH 7.4 buffer IP for 
22 h. The exposed films were dried at 50ºC for 24 h 
and subjected to FTIR analysis. 
 
Swelling Index Measurement 
The swelling index of the IPC films after exposure to 
different pH was determined by sequentially 
immersing the films in pH 1.2 for 2 h and pH 7.4 for 
22 h. The swelling index was calculated according to 
the formula 






Where, W1 is the initial weight of the film and W2 is 
the weight of the swollen film. 
 
Formulation of fluticasone tablets 
Preparation of core tablets 
Tablets (average weight 25 mg) containing 3 mg of 
fluticasone were prepared by wet granulation 
technique. Fluticasone and Avicel® pH 102 were 
granulated using CH:CMG solution (10% w/w) as 
binder. The granules were passed through #16 and 
dried at 50 ± 2ºC to 2-3% w/w residual moisture 
content. The dried granules were passed through #20 
sieve and fines were retained on #44 sieve. 10% w/w 
of fines was mixed with the granules. Magnesium 
stearate (1% w/w) was added to the granules. Tablets 
were compressed using biconvex 4mm convex 
punches in a six station rotary tablet compression 
machine (A K Industries, M207, Nakodar, India). 
These tablets were tested for dimensions (axial and 
radial diameters), hardness, friability and weight 
variation [16].  
 
Coating of fluticasone tablets  
The formulated fluticasone tablets containing 
CH:CMG solution as binder were coated with 
aqueous solutions containing respective CH:CMG 
ratio (composition same as IPC film) to obtain a 
weight gain of 10% w/w. The total polymer 
concentration was kept constant at 2.5% w/v. The 
coating solution was sprayed at a rate of 5 ml/min 
with the help of peristaltic pump using a spray gun of 
1 mm nozzle (Electrolab, PP201V, Mumbai, India) in 
a coating pan (12"diameter) being rotated at 18 rpm 
(AK Industries, M1107, Nakodar, India). Compressed 
air was introduced at a pressure of 1.5 kg/cm2. The 
inlet air temperature was maintained at 60°C. The 
inner surface of coating pan was modified by 
attaching inert tubes (8 mm diameter) from the centre 
to the periphery for easy rolling of tablets thereby 
ensuring efficient mass transfer of polymer. The 
coated tablets were also evaluated for weight 
variation, disintegration time. Further, the axial and 
radial diameters were measured as described above. 
 
In vitro release kinetics of fluticasone from coated 
tablets  
In vitro release of fluticasone from coated tablets was 
evaluated out using USP 30-NF25 (Dissolution 
Apparatus 1-basket method) utilizing temperature of 
37 ± 0.5°C with constant stirring rate of 50 rev/min in 
a pH progression media containing 2% v/v Tween 20 
to maintain sink conditions. pH progression consisted 
of exposing the tablets to buffer pH 1.2 IP for 2 h 
followed by buffer pH 7.4 IP for 3 h and buffer pH 
6.8 for further period of 19 h. Dissolution studies 
were also carried out in pH 1.2 (2 h), pH 7.4 (3 h) and 
pH 6.8 (containing 0.05 units of chitosanase solution 
in sodium acetate buffer pH 5.0) for a further period 
of 19 h. Aliquots (5 ml) were withdrawn at 
predetermined intervals and immediately analyzed by 
spectrophotometer at 232 nm. 
 
Mechanism for Drug Release  
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The mechanism of drug release during dissolution 
studies in pH progression media or in the presence of 
chitosanase was evaluated by using the Korsmeyer 
equation [17].  
               Mt/M∞   =       Ktn 
Where, Mt/M∞ = fractional release of drug, t =
 release time, k = kinetic constant, which 
incorporates structural and geometric 
characteristics of the device. 
 n = release exponent, which indicates the 
kinetic release. 
A value of 0.45 for ‘n’ indicates the case of diffusion-
controlled drug release (Fickian release). Case II 
transport or relaxation controlled delivery is indicated 
by a value of 0.89. Values of ‘n’ between 0.45 and 
0.89 are regarded as an indicator for the non-Fickian 
release or anomalous transport. The non-Fickian 
kinetics is suggestive of a combination of diffusion 
and polymer relaxation. In addition, Super Case II 
kinetics is indicated when the values of ‘n’ are greater 
than 0.89. 
 
Pharmacodynamic evaluation  
Sprague Dawley rats (200-250g) of 8-12 weeks age 
were used in the study. They were fed with standard 
laboratory chow diet and given water ad libitum. The 
experimental protocol was approved by Institutional 
Animal Ethics Committee of the Punjabi University, 
Patiala, India and the care and handling of the animals 
were in accordance with Committee for purpose of 
control and supervision of experimental animals 
(CPCSEA), Ministry of Environment and Forests, 
Government of India (Reg. No.- 107/1999/CPCSEA).  
 
Induction of colonic inflammation 
The rats were fasted for 48 h before the induction of 
ulcerative colitis. 2,4,6 Trinitro benzene sulphonic 
acid (TNBS) (20mg) was dissolved in 0.25 ml of 50% 
v/v ethanol. This solution was instilled into the colon 
(7 cm from the anus) of rats with the help of a 
catheter in order to induce ulcerative colitis [18]. The 
rats were monitored for three days without treatment 
to allow for the development of ulcerative colitis.  
 
Treatment of ulcerative colitis 
 The rats that weighed 80-100% of their initial weight 
(before TNBS instillation) were selected after 3 days 
as the ulcerative colitis positive animals. These rats 
were divided into two groups. Rats of Group I and 
Group II received oral administration of, respectively, 
normal saline (0.5 ml) or tablets coated with IPC 
films comprising 50:50 ratio of CH:CMG. The 
treatments were given once daily for five consecutive 
days.  
 
Assessment of colonic inflammation  
Colonic inflammation following rectal administration 
of TNBS as well as after different treatments (as 
detailed above) was assessed by the following 
parameters. 
 
Colon/ body weight (C/B) ratio 
 The rats were sacrificed on the sixth day (after five 
days of tablet administration) and distal colon 
segments (6 cm length) were resected, opened 
longitudinally and rinsed with iced phosphate buffer. 
The ratio of wet weight of the colon specimen to the 
body weight was calculated for each rat.  
 
Histopathological studies  
Tissue segments (1 cm in length) were fixed in 10% 
buffered formalin for histopathological studies. 
Histopathological studies were carried out using 
haematoxylin and eosin stains at Department of 
Pathology, Government Rajindra Hospital, Patiala, 
Punjab.  
 
Results and discussion 
Preparation and Characterization of CMG  
The prepared CMG was characterized by FTIR 
spectroscopy. The appearance of a peak at 1424 cm-1 
indicated the presence of –COO¯ ions (representing 
C=O stretch of –COO¯) in the CMG specimen 
(Figure 1C). This peak was absent in guar gum 
sample (Figure 1A) thus, indicating that 
carboxymethylation had been successfully carried out 
resulting in formation of CMG. The degree of 
substitution was calculated to be 0.27. 
 
Characterization of IPC films 
FTIR analysis 
The presence of peaks at 1560 cm-1 and 1422 cm-1 in 
the IR spectrograph of CH indicated the presence of –
NH3+ ions [19] and –COO¯ ions. These peaks could 
have arisen due to 15% acetylation of CH powder 
(Figure 1B). The presence of peaks at 1402.5 cm-1 
(due to –NH3+) and 1573.5 cm-1 (due to –COO—) in 
all CH-CMG IPC films suggested interaction between 
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–COO¯ groups of CMG and  –NH3+ groups in CH 
(Figs. 1D-F).  
 
 
Figure 1: FTIR spectra of Guar gum (A); Chitosan 
(B); Carboxymethyl Guar gum (C); complex 
formed by interacting CH and CMG in the ratio of 
60:40 (D); 50:50 (E); 40:60 (F). 
 
The spectrographs of IPC films containing 40:60 ratio 
of CH:CMG showed reduced intensity of peaks at 
1565 cm−1 and 1410 cm−1 after exposure to pH 1.2, 
thus indicating weakening of NH3+COO− interaction 
after exposure to acidic pH (Figure 2A). The 
spectrographs were observed to be similar in nature 
after exposure of these films to buffer pH 7.4 (Figure 
2B). The peak at 1410 cm−1 corresponding to –COO− 
was observed to considerably decrease in intensity 
and the peak at 1565 cm−1 corresponding to –NH3+ 
ions was found to be completely abolished in the IPC 
films comprising of 60:40 ratio of CH:CMG after 
exposure to pH 1.2. This suggested total breakdown 
of NH3+COO− linkages in these IPC films (Figure 1E 
and F). However, the IR spectrograph of film 
comprising 50:50 ratio of CH:CMG did not reveal 
any change in the intensity of peaks at 1402.4 cm-1  
and 1572.2 cm-1  (Figure 2 C and D). This indicated 
that the interaction in IPC films formed by interacting 
50:50 ratio of CH:CMG was not cleaved after 




Figure 2 FTIR spectra of IPC films (CH:CMG) 
after treatment with pH 1.2 and 7.4 buffers 
respectively: 40:60 (A) and (B); 50:50 (C) and (D); 
60:40 (E) and (F). 
Swelling Index studies  
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The CH-CMG IPC films were found to exhibit 
swelling in acidic medium as well as in basic medium 
(Table 1). Swelling is favored by the protonation and 
repulsion of chitosan free ammonium groups. In 
acidic media, the polyacid is neutralized and due to 
the free ammonium groups of CH, excess positive 
charges appear inside the gel resulting in fast drug 
release [20]. However, IPC films containing any ratio 
of CH:CMG exhibited considerably less swelling in 
pH 7.4 as compared to pH 1.2. This can be ascribed to 
the fact that prolonged immersion in water produced 
segmental mobility of the interpolymer chains in the 
swollen state, which allowed the completion of 
interpolymer reaction between CH and CMG 
eventually leading to shrinkage after exposure to pH 
7.4. A decrease in swelling was observed after 
exposure to pH 1.2 as well as pH 7.4 with an increase 
in the CMG concentration except in the IPC films 
comprising 30:70 or and 20:80 ratio of CH:CMG, 
which showed a greater swelling. Similar results have 
been reported earlier where carboxymethyl tamarind 
kernel powder and chitosan IPC films were observed 
to exhibit greater swelling with an increase in the 
concentration of carboxymethyl tamarind kernel 
powder [8].  
 
Physical evaluation of tablets  
The average weight of uncoated core tablets was 
29.72 ± 0.43 mg. The acceptance value calculated 
was 11.98% which was well below the maximum 
15% USP tolerance limit [16] Hence, the tablets 
passed the weight variation test. Hardness of the 
tablets was 4.5 ± 0.5 kg/cm2 and friability was found 
to range from 0.41 to 0.52% w/w. The axial and radial 
diameters, respectively, ranged from 1.75 to 1.80 mm 
and 3.98 to 4.02 mm. The uncoated tablets prepared 
by using 10% w/w CH:CMG as a binder started 
showing signs of cracking within 30 min of exposure 
to 0.1M HCl.  
The average weight of coated tablets was 33.09 ± 
0.17 mg. The acceptance value calculated was 
11.31%. Hence, the tablets passed the weight 
variation test. The axial and radial diameters of coated 
tablets, respectively, ranged from 2.02 to 2.08 mm 
and 4.01 to 4.15 mm. Although, these tablets 
exhibited swelling, they didn’t soften or crack after 
exposure to 0.1M HCl for 2 h.  
Table 1. Swelling studies of CH:CMG IPC films 
Swelling Index 
CH:CMG ratio 
pH 1.2 pH 7.4 
80:20 5.27 ± 0.37 3.58 ± 0.60 
70:30 4.58 ± 0.15 2.83 ± 0.14 
60:40 3.02 ± 0.15 1.35 ± 0.16 
50:50 2.12 ± 0.21 0.83 ± 0.49 
40:60 3.65 ± 0.19 1.02 ± 0.15 
30:70 4.44 ± 1.05 2.84 ± 0.53 
20:80 5.32 ± 0.41 3.89 ± 0.38 
 
In vitro dissolution studies  
The in vitro drug release profile is depicted in Figure 
3. The uncoated tablets started releasing fluticasone 
within 1 h in pH 1.2. Since, the drug release from 
uncoated tablets after 2 hrs was found to be more than 
10% hence uncoated tablets could not be used for 
colon targeting [16]. Therefore, these batches were 
coated with respective ratio of CH:CMG to yield IPC 
films. The tablets coated with 60:40, 50:50 or 40:60 
ratio of CH:CMG released, respectively, 5.60 ± 
0.29%, 2.34 ± 0.14% and 5.05± 0.25% fluticasone in 
pH 1.2. The observation of <10% drug released in 
acidic media16) indicated fulfillment of drug release 
criteria expected of enteric tablets These batches, 
respectively, released 15.11 ± 0.58%, 8.01 ± 0.17% 
and 13.08 ± 0.021% fluticasone in pH 7.4 after 5 hr. 
Further, these tablets released 53.87 ± 0.33%, 37.86 ± 
0.42% and 49.63 ± 0.61% fluticasone, respectively in 
pH 6.8 after 24 h. This was supported with the FTIR 
spectra of IPC films prepared from 50:50 ratio of 
CH:CMG that did not reveal any decrease in the 
intensity of peaks characteristic of CH-CMG 
interpolymer complexation (Figure 3C and D). 
 
In vitro dissolution studies in presence of 
chitosanase  
The presence of chitosanase increased the amount of 
fluticasone released from 50:50 (CH:CMG) IPC film 
coated tablets. The final exposure of these tablets to 
pH 6.8 containing chitosanase enzyme for 19 h 
eventually released 92.43% fluticasone. Chitosanase 
enzyme activity requires the presence of free amino 
group in CH [21]. However, since the amino group of 
CH molecule is ionically complexed with –COO¯ 
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groups of CMG, complete hydrolysis of CH can not 
be expected. This seems to be responsible for the 



























60:40 uncoated 60:40 coated 50:50 uncoated 50:50 coated
50:50 (chitosanase) 40:60 uncoated 40:60 coated
 
Figure 3. Cumulative  fluticasone released (%) 
from uncoated tablets and tablets coated with IPC 
films comprising 40:60, 50:50 or 60:40 ratio of 
CH:CMG containing respective ratio of CH:CMG 
as binder. 
 
Mechanism of drug release  
The release kinetics of fluticasone from coated tablets 
containing CH-CMG solution as binder and coated 
with 50:50 ratio of CH:CMG was analyzed by  
Korsmeyer–Peppas model [17]. The value of r2 was 
found to lie above 0.9 and the value of release 
exponent was more than 1.0. This indicated that the 
drug release can be ascribed to a Super Case II 
transport. Super Case II transport is reported to be 
exhibited when diffusion and relaxation rates are 
comparable [22]. Therefore, it can be suggested that 
the interpolymer complexation between CH and 
CMG was resistant to different pH media and release 




Colon/Body weight (C/B) ratio  
The Colon/Body weight (C/B) ratio was determined 
for quantitative evaluation of the inflammatory colitis 
of different groups. The C/B ratio after the 
intracolonic administration of TNBS was significantly 
(p<0.05) increased as compared to that after 
administration of saline. The C/B ratio after oral 
administration of fluticasone tablets coated with 
CH:CMG (50:50) IPC films significantly decreased in 
the TNBS-induced colitis rats. Figure 4 represents the 























Normal group TNBS induced colitis group Coated Tablets  
 
Figure 4 Colon/Body weight (C/B) ratio 
determined after 5 days of drug administration. 




The histology of normal colon is depicted in Figure 5. 
The four layers of colon wall are mucosa, submucosa, 
muscularis externa and serosa. The section of the 
colon shows temporary folds of the mucosa and 
submucosa (Figure 5A). As is evident from Fig 5B, 
the ulcerative colitis induced colon showed shedding 
of epithelium and lymphocytic infiltration in lamina 
propria. The inflammation was spread over the 
mucosa, submucosa, muscle layer and serosa. Oral 
administration of coated fluticasone tablets resulted in 
a marked decrease in the extent and severity of 
colonic damage. The histopathological features of 
colon clearly indicated that the morphological 
disturbances associated with TNBS administration 
were corrected after five days of oral administration 
of tablets coated with 50:50 CH:CMG (Figure 5C). 
The tablets coated with 50:50 ratio of CH:CMG can 
be envisaged to offer a great promise for colon 
delivery of fluticasone, thereby providing high local 
drug concentration in the distal part of gastrointestinal 
tract for longer durations for effective therapy of IBD. 
 





Figure 5. Light microscopic photographs of colon: normal colon (A); TNBS induced ulcerative colitis (B); 
after treatment with coated fluticasone tablets (C). 
 
Conclusion 
The results of the present study indicated that the 
tablets coated with IPC films containing 50:50 or 
40:60 ratio of CH:CMG were effectively restraining 
the in vitro release of fluticasone under conditions 
mimicking stomach and small intestine as compared 
to uncoated tablets. The ability of the IPC films in 
providing the observed release characteristics to 
fluticasone core tablets was correlated with the ability 
of –NH3+ groups of CH to form complex with –COO¯ 
groups of CMGTKP and the stability of these 
complexes in acidic media. The tablets coated with 
50:50 ratio of CH:CMG can be envisaged to offer a 
great promise for colon delivery of fluticasone, 
thereby providing drug concentration in the distal part 
of gastrointestinal tract for longer durations for 
effective therapy of IBD. 
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